Acquisition (action)
AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio
AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech
Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC
Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion
Asensus Surgical to be Acquired by KARL STORZ for $0.35 per Share in Cash
Asensus Surgical, KARL STORZ, acquisition, merger, surgical robotics, digital solutions, operating room, laparoscopy, LUNA system
AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment
AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology
GSK Acquires Oligonucleotide Partner Elsie for Up to $50 Million
GSK, Elsie Biotechnologies, oligonucleotide platform, acquisition, biotech, pharmaceuticals
ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition
ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing
Merck & Co. Revives Ophthalmology Efforts with $3 Billion EyeBio Acquisition ###
Merck & Co., EyeBio, Ophthalmology, Trispecific antibody, Restoret, Acquisition, Biotechnology, Pharmaceuticals
Asahi Kasei Acquires Calliditas Therapeutics for $1.1 Billion to Expand in Rare Disease Market
Asahi Kasei, Calliditas Therapeutics, acquisition, rare disease market, kidney disease, Tarpeyo, IgA nephropathy, pharmaceutical growth strategy
Nuvation Bio Unveils Groundbreaking Cancer Drug Data from AnHeart Acquisition in China
Nuvation Bio, AnHeart, cancer drug, pivotal data, China, acquisition, clinical trials
Cytokinetics’ Royalty Agreement Dampens Merger and Acquisition Hopes, Say Investors
Cytokinetics, Merger and Acquisition (M&A), Royalty Agreement, Investors, Biotech Industry